5 results about "Low density lipoprotein cholesterol level" patented technology

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

The application belongs to the technical field of preoperative management of weight loss surgery, and particularly relates to a preoperative training system for obese patients and application thereof. The application provides a preoperative training system for obese patients, which comprises a physiological system evaluation module, a movement planning module and a nutrition module. The preoperative training system according to the application can significantly reduce the fasting blood glucose level, triglyceride level and low-density lipoprotein cholesterol level of obese patients after metabolic and weight loss surgery, thereby effectively improving the metabolic disorder of the patients, which has important clinical significance for improving the postoperative recovery process of obese patients, improving the quality of life and consolidating the long-term efficacy of weight loss surgery. The preoperative training system according to the application fills the technical gap in the preoperative management of obese patients, provides a non-invasive and efficient auxiliary system, and has a broad clinical application prospect.

The embodiment of the application discloses a traditional Chinese medicine composition for treating hyperlipidemia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperlipidemia is prepared from the following traditional Chinese medicinal materials in parts by weight: 10-30 parts of Coptis chinensis, 20-60 parts of Allium bakeri and 10-30 parts of Curcuma zedoaria. The composition is obtained by refining three medicines from an existing compound preparation based on the theory of 'phlegm and blood stasis' in traditional Chinese medicine. Pharmacodynamic experiments prove that the composition can significantly reduce the levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in serum of hyperlipidemia mice, increase the level of high-density lipoprotein cholesterol (HDL-C), improve liver steatosis and lipid deposition, and has better lipid-lowering and liver-protecting effects than the original compound preparation, is slightly better than the positive drug fenofibrate in increasing HDL-C, and has good application prospect due to refined components, simple preparation process and reduced cost.

This invention belongs to the field of traditional Chinese medicine preparations, specifically relating to a traditional Chinese medicine composition for weight loss, its preparation method, and its application. The traditional Chinese medicine composition of this invention is made from the following raw materials in parts by weight: 15-25 parts Angelica sinensis, 8-12 parts Astragalus membranaceus, 8-12 parts Citrus reticulata peel, and 8-12 parts Nelumbo nucifera leaf. In this invention, Angelica sinensis is the principal herb, promoting blood circulation and unblocking collaterals; Astragalus membranaceus is the assistant herb, tonifying qi and promoting digestion; Citrus reticulata peel is the adjuvant herb, regulating qi and resolving phlegm; and Nelumbo nucifera leaf is the guiding herb, clearing heat and promoting diuresis. The entire formula works synergistically to resolve phlegm, promote diuresis, strengthen the spleen, and soothe the liver. Animal experiments have shown that the composition of this invention can significantly reduce weight gain, fat accumulation, and liver fat content in obese mice, improve oral glucose tolerance, and reduce serum triglyceride and low-density lipoprotein cholesterol levels. At the same time, it can significantly restore the diversity of intestinal flora α, increase the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, effectively improve the intestinal flora disorder induced by a high-fat diet in mice, and the remodeled intestinal flora can play a role in weight loss. Thus, this invention provides a safe, effective, and palatable new traditional Chinese medicine compound solution for metabolic disorders and intestinal microecological imbalance.